Los Angeles Capital Management
PRVL

Los Angeles Capital Management’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Los Angeles Capital Management’s Portfolio PRVL Stock Details PRVL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-25,705
Closed -$593K – 1695
2020
Q4 		$593K Buy
25,705
+3,772
+17% +$47.8K ﹤0.01% 1137
2020
Q3 		$223K Buy
21,933
+1,350
+7% +$18.1K ﹤0.01% 1370
2020
Q2 		$307K Buy
20,583
+7,503
+57% +$116K ﹤0.01% 1285
2020
Q1 		$159K Buy
+13,080
New +$208K ﹤0.01% 1229

Los Angeles Capital Management's PRVL Position: Q1 2021 in Review

Los Angeles Capital Management sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 25,705 shares — an estimated $593K sold.

Los Angeles Capital Management first reported a position in PRVL in Q1 2020 and held it in 4 quarters. The position peaked at $593K in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

  • Los Angeles Capital Management reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Los Angeles Capital Management sold 25,705 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $593K.
  • Los Angeles Capital Management first reported a position in Prevail Therapeutics Inc. Common Stock in Q1 2020 and held it in 4 quarters.
  • Los Angeles Capital Management's Prevail Therapeutics Inc. Common Stock position peaked at $593K in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on Los Angeles Capital Management's 13F filing for Q1 2021, filed 5 May 2021.